Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 3
2013 3
2014 2
2015 1
2016 5
2017 4
2018 5
2019 1
2020 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. Cushman WC, et al. Hypertension. 2012 Aug;60(2):310-8. doi: 10.1161/HYPERTENSIONAHA.111.188284. Epub 2012 Jun 18. Hypertension. 2012. PMID: 22710649 Clinical Trial.
Azilsartan medoxomil, an effective, long-acting angiotensin II receptor blocker, is a new treatment for hypertension that is also being developed in fixed-dose combinations with chlorthalidone, a potent, long-acting thiazide-like diuretic. ...Adverse events leading …
Azilsartan medoxomil, an effective, long-acting angiotensin II receptor blocker, is a new treatment for hypertension that is a …
Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis.
Wang JG, Zhang M, Feng YQ, Ma CS, Wang TD, Zhu ZM, Kario K. Wang JG, et al. J Clin Hypertens (Greenwich). 2021 May;23(5):901-914. doi: 10.1111/jch.14227. Epub 2021 Feb 20. J Clin Hypertens (Greenwich). 2021. PMID: 33609077 Free PMC article.
The ranking plot shows that azilsartan medoxomil 80 mg had a possibility of 99% being the best in the class. ...In conclusion, angiotensin-receptor blockers had different blood pressure lowering efficacy. The newest angiotensin-receptor blocker azilsartan …
The ranking plot shows that azilsartan medoxomil 80 mg had a possibility of 99% being the best in the class. ...In conclusion, …
A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone.
Weber MA, Sever P, Juhasz A, Roberts A, Cao C. Weber MA, et al. J Renin Angiotensin Aldosterone Syst. 2018 Jul-Sep;19(3):1470320318795000. doi: 10.1177/1470320318795000. J Renin Angiotensin Aldosterone Syst. 2018. PMID: 30175930 Free PMC article. Clinical Trial.
INTRODUCTION: We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertension. ...RESULTS: Patients ( N=551; mean age 59 years; 51.7% men) were randomly assigned to placebo plus chlorthalidone ( n=184), azilsartan …
INTRODUCTION: We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertensio …
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, Song E, Kupfer S. Bakris GL, et al. Am J Med. 2012 Dec;125(12):1229.e1-1229.e10. doi: 10.1016/j.amjmed.2012.05.023. Epub 2012 Aug 30. Am J Med. 2012. PMID: 22939358 Clinical Trial.
METHODS: This is a randomized, double-blind, titrate-to-target blood pressure trial comparing the single-pill combination of azilsartan medoxomil and chlorthalidone versus co-administration of azilsartan medoxomil and hydrochlorothiazide in participant …
METHODS: This is a randomized, double-blind, titrate-to-target blood pressure trial comparing the single-pill combination of azilsartan …
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. White WB, et al. Hypertension. 2011 Mar;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402. Epub 2011 Jan 31. Hypertension. 2011. PMID: 21282560 Clinical Trial.
Azilsartan medoxomil is an angiotensin receptor blocker (ARB) being developed for hypertension treatment. ...Azilsartan medoxomil could provide higher rates of hypertension control within the ARB class....
Azilsartan medoxomil is an angiotensin receptor blocker (ARB) being developed for hypertension treatment. ...Azilsartan …
Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.
Neutel JM, Cushman WC, Lloyd E, Barger B, Handley A. Neutel JM, et al. J Clin Hypertens (Greenwich). 2017 Sep;19(9):874-883. doi: 10.1111/jch.13009. Epub 2017 Jul 6. J Clin Hypertens (Greenwich). 2017. PMID: 28681550 Free PMC article. Clinical Trial.
This 52-week, randomized, open-label study evaluated long-term safety/tolerability of fixed-dose combination azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs fixed-dose combination olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with essential hype …
This 52-week, randomized, open-label study evaluated long-term safety/tolerability of fixed-dose combination azilsartan medoxomil …
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
Bakris GL, Zhao L, Kupfer S, Juhasz A, Hisada M, Lloyd E, Oparil S. Bakris GL, et al. J Clin Hypertens (Greenwich). 2018 Apr;20(4):694-702. doi: 10.1111/jch.13230. Epub 2018 Mar 4. J Clin Hypertens (Greenwich). 2018. PMID: 29504252 Free PMC article. Clinical Trial.
An open-label, long-term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. ...
An open-label, long-term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs olmesar …
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
Weber MA, White WB, Sica D, Bakris GL, Cao C, Roberts A, Kupfer S. Weber MA, et al. Blood Press Monit. 2014 Apr;19(2):90-7. doi: 10.1097/MBP.0000000000000027. Blood Press Monit. 2014. PMID: 24445723 Free PMC article. Clinical Trial.
All treatments were well tolerated, and adverse events did not increase with the azilsartan medoxomil doses. Edema or fluid retention was less common in both combination groups (2.6 and 2.7%) than with placebo plus amlodipine (7.6%). CONCLUSION: Coadministration of …
All treatments were well tolerated, and adverse events did not increase with the azilsartan medoxomil doses. Edema or fluid re …
Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.
Ferdinand KC, Bakris GL, Cushman WC, Weber MA, Lloyd E, Wu J, White WB. Ferdinand KC, et al. Am J Cardiol. 2018 Nov 1;122(9):1496-1505. doi: 10.1016/j.amjcard.2018.07.022. Epub 2018 Aug 4. Am J Cardiol. 2018. PMID: 30217371 Free article. Clinical Trial.
Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and …
Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsar …
Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial.
Collier DJ, Juhasz A, Agabiti-Rosei E, Lloyd E, Hisada M, Zhao L, Kupfer S, Caulfield MJ. Collier DJ, et al. J Clin Hypertens (Greenwich). 2018 Oct;20(10):1473-1484. doi: 10.1111/jch.13376. Epub 2018 Oct 9. J Clin Hypertens (Greenwich). 2018. PMID: 30302936 Free PMC article. Clinical Trial.
Patients with grade 2-3 essential hypertension and postplacebo mean clinic systolic blood pressure (SBP) 160-190 mm Hg and 24-hour SBP 140-175 mm Hg by ambulatory blood pressure monitoring (ABPM) received 40 mg azilsartan medoxomil (AZL-M) monotherapy for 4 weeks. " …
Patients with grade 2-3 essential hypertension and postplacebo mean clinic systolic blood pressure (SBP) 160-190 mm Hg and 24-hour SBP 140-1 …
27 results